The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
Authors
Keywords
Uveitis, Immune checkpoint inhibitor, Kinase inhibitor, Melanoma, Targeted treatment
Journal
EUROPEAN JOURNAL OF CANCER
Volume 144, Issue -, Pages 215-223
Publisher
Elsevier BV
Online
2020-12-26
DOI
10.1016/j.ejca.2020.11.027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database
- (2020) Céline Anquetil et al. JOURNAL OF AUTOIMMUNITY
- Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series
- (2019) Jenna May Kim et al. OPHTHALMOLOGY
- Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy
- (2019) Karen Bitton et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- CHECKPOINT INHIBITOR IMMUNE THERAPY
- (2018) Lauren A. Dalvin et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Incomplete Vogt–Koyanagi–Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma
- (2018) Panagiotis T. Diamantopoulos et al. MELANOMA RESEARCH
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review
- (2017) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Checkpoint inhibitor-induced uveitis: a case series
- (2017) Christopher D. Conrady et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
- (2017) James Larkin et al. ONCOLOGIST
- Ocular toxicities of MEK inhibitors and other targeted therapies
- (2016) N. Stjepanovic et al. ANNALS OF ONCOLOGY
- MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
- (2016) U. Urner-Bloch et al. EUROPEAN JOURNAL OF CANCER
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma – Case Series and Review
- (2016) F. Fierz et al. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis
- (2016) Carlos Alves et al. OPHTHALMIC RESEARCH
- Big Data and Uveitis
- (2016) Cecilia S. Lee et al. OPHTHALMOLOGY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib
- (2014) Christina H. Choe et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Incidence and Prevalence of Uveitis
- (2013) Nisha R. Acharya et al. JAMA Ophthalmology
- Understanding uveitis: The impact of research on visual outcomes
- (2011) Marc D. de Smet et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now